おすすめの製品
詳細
SOLVO Biotechnology offers ready-to-use assay kits for efflux and uptake transporters. SOLVO′s PREDIVEZ Vesicular Transport Assay Kits are suitable for efflux transporter inhibition studies. The kits are designed to test the inhibitory effect of one or more test compounds on the vesicular transport of a probe substrate. In most cases a fluorescent probe substrate is included. Kits contain all reagents and solutions necessary to conduct the drug-transporter interaction assay of need.
アプリケーション
The PREDIVEZTM Vesicular Transport Kit is a simple and powerful tool to investigate drug transporter interactions. It provides information on any interaction between the ABC transporter and the drug candidate that would affect the transport of the fluorescent or radiolabeled or cold.
PREDIVEZTM vesicular transport kits are available in three sizes 3, 6 or 9 compound sizes. The kits contain the sufficient amount of reagents and membrane preparations needed for the testing of 3 compounds per 96-well plate. Each kit is accompanied by a CD that includes the assay protocol, an Excel spreadsheet with a data processing template, SDS and the inhibition curves with reference compounds.
PREDIVEZTM vesicular transport kits are available in three sizes 3, 6 or 9 compound sizes. The kits contain the sufficient amount of reagents and membrane preparations needed for the testing of 3 compounds per 96-well plate. Each kit is accompanied by a CD that includes the assay protocol, an Excel spreadsheet with a data processing template, SDS and the inhibition curves with reference compounds.
物理的形状
Supplied as frozen membrane vesicles, containing 5 mg/ml membrane protein, labeled with volume, catalog number (transporter), date of production, protocols and necessary reagents sufficent for the analysis of 3, 6, or 9 test compounds
法的情報
SOLVO Biotechnology, Inc.より提供。
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Carc. 2 - Eye Dam. 1 - Lact. - Met. Corr. 1 - Repr. 1A - Skin Corr. 1B
保管分類コード
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
毒物及び劇物取締法
キットコンポーネントの情報を参照してください
PRTR
キットコンポーネントの情報を参照してください
消防法
キットコンポーネントの情報を参照してください
労働安全衛生法名称等を表示すべき危険物及び有害物
キットコンポーネントの情報を参照してください
労働安全衛生法名称等を通知すべき危険物及び有害物
キットコンポーネントの情報を参照してください
カルタヘナ法
キットコンポーネントの情報を参照してください
Jan Code
キットコンポーネントの情報を参照してください
最新バージョンのいずれかを選択してください：
Márton Jani et al.
Journal of pharmaceutical sciences, 100(1), 94-97 (2010-06-25)
Ivermectin is an antiparasitic drug frequently administered to humans. It has a limited brain exposure that is attributed to the efflux activity of ABCB1/Abcb1. ABCG2/Abcg2 is also a major transporter present in most pharmacologically important barriers. However, interaction of ivermectin
Albert Mennone et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(10), 1673-1678 (2010-07-06)
Breast cancer resistance protein (Bcrp) is a member of the ATP-binding cassette membrane transporter family, which is expressed apically in liver, kidney, and intestine epithelium. Recent reports suggest that in addition to xenobiotics, porphyrins, and food toxins, Bcrp can also
Márton Jani et al.
Biological & pharmaceutical bulletin, 32(3), 497-499 (2009-03-03)
The pharmacokinetics of sulfasalazine, an anti-inflammatory drug is influenced by ATP-binding cassette G2 (ABCG2) (breast cancer resistance protein (BCRP), mitoxantrone resistance protein (MXR)) both in vitro and clinically. Due to its low passive permeability, the intracellular concentration of sulfasalazine is
E Kis et al.
Annals of the rheumatic diseases, 68(7), 1201-1207 (2008-04-10)
Earlier publications have suggested a possible role for the efflux transporter breast cancer resistance protein (BCRP) in acquired resistance to disease-modifying antirheumatic drugs (DMARDs) such as leflunomide and its metabolite A771726 (teriflunomide). However, there is no direct evidence that BCRP
Kumie Kage et al.
International journal of cancer, 97(5), 626-630 (2002-01-25)
Breast cancer resistance protein (BCRP) is a half-molecule ABC transporter highly expressed in mitoxantrone-resistant cells. In our study we established PA317 transfectants expressing Myc-tagged BCRP (MycBCRP) or HA-tagged BCRP (HABCRP). The exogenous BCRP protein migrated as a 70-kDa protein in
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）